Infliximab for the treatment of refractory noninfectious uveitis: A study of 88 patients with long-term follow-up

Ophthalmology

Volumn 121, Issue 1, 2014, Pages 358-364

  Kruh, Jonathan N ^a,b   Yang, Paul ^a,b   Suelves, Ana M ^a,b   Foster, C Stephen ^a,b,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; AUTOIMMUNE HEPATITIS; COHORT ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTION; INFUSION RELATED REACTION; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REFRACTORY NONINFECTIOUS UVEITIS; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; UVEITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; UVEITIS;

EID: 84891619597     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.07.019     Document Type: Article

References (45)

1. R.B. Nussenblatt The natural history of uveitis Int Ophthalmol 14 1990 303 308
2. D.C. Gritz, and I.G. Wong Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study Ophthalmology 111 2004 491 500
3. M. Croft The role of TNF superfamily members in T-cell function and diseases Nat Rev Immunol 9 2009 271 285
4. T.M. Carlos, B.R. Schwartz, and N.L. Kovach et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells Blood 76 1990 965 970
5. J.L. Salyer, J.F. Bohnsack, and W.A. Knape et al. Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration Am J Pathol 136 1990 831 841
6. F.M. Brennan, and I.B. McInnes Evidence that cytokines play a role in rheumatoid arthritis J Clin Invest 118 2008 3537 3545
7. E.M. Paleolog, S. Young, and A.C. Stark et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis Arthritis Rheum 41 1998 1258 1265
8. P. Charles, M.J. Elliott, and D. Davis et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 1999 1521 1528
9. M. Feldmann, and R.N. Maini Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases Nat Med 9 2003 1245 1250
10. X. Chen, and J.J. Oppenheim Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity FEBS Lett 585 2011 3611 3618
11. C.A. Notley, and M.R. Ehrenstein The yin and yang of regulatory T cells and inflammation in RA Nat Rev Rheumatol 6 2010 572 577
12. S. Sugita, Y. Yamada, and S. Kaneko et al. Induction of regulatory T cells by infliximab in Behcet's disease Invest Ophthalmol Vis Soc 52 2011 476 484
13. A.F. de Vos, M.A. van Haren, and C. Verhagen et al. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat Invest Ophthalmol Vis Sci 35 1994 1100 1106
14. V. Pérez-Guijo, M. Santos-Lacomba, and M. Sanchez-Hernandez et al. Tumour necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27 Curr Med Res Opin 20 2004 155 157
15. G. Sartani, P.B. Silver, and L.V. Rizzo et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming Invest Ophthalmol Vis Sci 37 1996 2211 2218
16. A.D. Dick, P.G. McMenamin, and H. Körner et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina Eur J Immunol 26 1996 1018 1025
17. A.D. Dick, J.V. Forrester, J. Liversidge, and A.P. Cope The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU) Prog Retin Eye Res 23 2004 617 637
18. K. Koizumi, V. Poulaki, and S. Doehmen et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo Invest Ophthalmol Vis Sci 44 2003 2184 2191
19. A. Heiligenhaus, S. Thurau, and M. Hennig et al. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease Graefes Arch Clin Exp Ophthalmol 248 2010 1531 1551
20. R. Maini, E.W. St Clair, and F. Breedveld ATTRACT Study Group Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial Lancet 354 1999 1932 1939
21. J. Braun, J. Brandt, and J. Listing et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis Rheum 48 2003 2224 2233
22. M. Girardin, M. Manz, and C. Manser et al. First-line therapies in inflammatory bowel disease Digestion 86 Suppl 2012 6 10
23. W. Reinisch, G. Van Assche, and R. Befrits et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus J Crohns Colitis 6 2012 248 258
24. B.E. Sands, F.H. Anderson, and C.N. Bernstein et al. Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
25. K.E. Hostettler, U. Studler, M. Tamm, and M.H. Brutsche Long-term treatment with infliximab in patients with sarcoidosis Respiration 83 2012 218 224
26. J.R. Maneiro, E. Salgado, J.J. Gomez-Reino, L. Carmona, and BIOBADASER Study Group Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review Semin Arthritis Rheum 42 2012 89 103
27. N. Ruperto, D.J. Lovell, R. Cuttica Paediatric Rheumatology INternational Trials Organization (PRINTO), and Pediatric Rheumatology Collaborative Study Group (PRCSG) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open label treatment extension Ann Rheum Dis 69 2010 718 722
28. G. De Marco, V. Gerloni, and I. Pontikaki et al. Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy [in Italian] Reumatismo 59 2007 50 56
29. S. Adler, I. Baumgartner, and P.M. Villiger Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis Arthritis Care Res (Hoboken) 64 2012 607 611
30. M. Naganuma, A. Sakuraba, and T. Hisamatsu et al. Efficacy of infliximab for the induction and maintenance of remission in intestinal Beçhet's disease Inflamm Bowel Dis 14 2008 1259 1264
31. N. Pipitone, I. Olivieri, and A. Padula et al. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature Arthritis Rheum 59 2008 285 290
32. P. Artornsombudh, O. Gevorgyan, and A. Payal et al. Infliximab treatment of patients with birdshot retinochoroidopathy Ophthalmology 120 2013 588 592
33. E.B. Suhler, J.R. Smith, and M.S. Wertheim et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes Arch Ophthalmol 123 2005 903 912
34. A. Arida, K. Fragiadaki, E. Giavri, and P.P. Sfikakis Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients Semin Arthritis Rheum 41 2011 61 70
35. Y. El-Shabrawi, and J. Hermann Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis Ophthalmology 109 2002 2342 2346
36. S. Ohno, S. Nakamura, and S. Hori et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis J Rheumatol 31 2004 1362 1368
37. S. Sukumaran, K. Marzan, B. Shaham, and A. Reiff High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol [serial online] 2012 2012 765380 Available at: http://www.hindawi.com/isrn/rheumatology/ 2012/765380/ Accessed July 3, 2013
38. P. Tynjälä, P. Lindahl, and V. Honkanen et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis Ann Rheum Dis 66 2007 548 550
39. J.C. Richards, M.L. Tay-Kearney, K. Murray, and P. Manners Infliximab for juvenile idiopathic arthritis-associated uveitis Clin Experiment Ophthalmol 33 2005 461 468
40. P. Seve, E. Mennesson, and J.D. Grange et al. Infliximab in serpiginous choroiditis [letter] Acta Ophthalmol 88 2010 e342 e343
41. A. Joseph, D. Raj, and H.S. Dua et al. Infliximab in the treatment of refractory posterior uveitis Ophthalmology 110 2003 1449 1453
42. Standardization of Uveitis Nomenclature (SUN) Working Group Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop Am J Ophthalmol 140 2005 509 516
43. E.B. Suhler, J.R. Smith, and T.R. Giles et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial [letter] Arch Ophthalmol 127 2009 819 822
44. Y. Tanaka Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 72 Suppl 2013 ii124-7
45. J.A. Singh, D.E. Furst, and A. Bharat et al. 2012 update of the 2008 American College of Rheumatology recommendation for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 64 2012 625 639